Guanfacine

證據等級: L5

預測適應症: 7 個

Guanfacine: From ADHD to Tourette Syndrome

One-Sentence Summary

Guanfacine is a selective alpha-2A adrenergic receptor agonist with an established clinical role in ADHD and related neurodevelopmental conditions. This evidence pack screened 7 TxGNN-predicted indications for guanfacine; the highest-scoring candidate (faciodigitogenital syndrome) had zero supporting evidence and is not viable, so this report focuses on Tourette Syndrome, the candidate with the strongest evidentiary support — 3 clinical trials (including a completed Phase 3 RCT) and 20 publications, including clinical guidelines that already recommend alpha-2 agonists for tic suppression.

Quick Overview

Item	Content
Original Indication	Not available in this evidence pack (drug not licensed/marketed in Taiwan; see Data Gaps)
Predicted New Indication	Tourette Syndrome
TxGNN Prediction Score	99.27%
Evidence Level	L1
Market Status (Taiwan)	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action data (DrugBank MOA field) is not available for guanfacine in this evidence pack (Data Gap DG002). However, the assembled clinical evidence itself describes guanfacine as a selective alpha-2A adrenergic receptor agonist acting on the prefrontal cortex, strengthening top-down regulation of attention and impulse-control circuits.

Guanfacine’s established clinical footprint is centered on ADHD and related neurodevelopmental conditions — reflected throughout this pack by ADHD-focused trials such as NCT04085172 (a completed Phase 4 RCT of guanfacine extended-release in children/adolescents with ADHD) and NCT03258476 (referencing guanfacine ER by its brand name, Intuniv™). Tourette syndrome and chronic tic disorders overlap heavily with ADHD both clinically and pathophysiologically: both are framed as disorders of cortico-striato-thalamo-cortical circuit dysregulation, and tic disorders carry very high rates of ADHD comorbidity.

This is not a purely novel, model-only hypothesis — guanfacine already has a multi-decade history of trial-based use specifically for tic suppression in Tourette syndrome, making the mechanistic extension from ADHD to Tourette syndrome a clinically mature one rather than speculative repurposing.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00004376	Phase 3	Completed	35	Double-blind, placebo-controlled evaluation of guanfacine safety/efficacy in children and adolescents with Tourette syndrome or other chronic tic disorder, and ADHD
NCT01547000	Phase 4	Completed	34	Multi-site pilot study of extended-release guanfacine (Intuniv) tolerability and efficacy in children with tic disorders/Tourette syndrome
NCT01172288	Phase 2	Completed	31	Trial drug is N-acetylcysteine (NAC), not guanfacine — population overlap only (children with Tourette syndrome), not direct guanfacine evidence

Literature Evidence

PMID	Year	Type	Journal	Key Findings
12469007	2002	RCT (double-blind, placebo-controlled)	Clinical Neuropharmacology	4-week pilot RCT of guanfacine in 24 children with Tourette syndrome; improved tic severity and neuropsychological measures post-treatment
7559307	1995	Clinical experience	J Am Acad Child Adolesc Psychiatry	Preliminary clinical experience of guanfacine for comorbid ADHD and Tourette syndrome, without tic exacerbation seen with stimulants
34757514	2022	Guideline	Eur Child Adolesc Psychiatry	European clinical guidelines for Tourette syndrome pharmacological treatment (v2.0), including alpha-2 agonists
31061209	2019	Systematic Review	Neurology	Systematic evaluation of tic treatment efficacy and risks in Tourette syndrome and chronic tic disorders
34286606	2021	Systematic Review	J Psychopharmacol	Quality-of-evidence review of pharmacological treatments for Tourette syndrome in children and adults
40489853	2025	Narrative Review	Medicine	Review of Phase III/IV trials for pharmacological treatment of Tourette syndrome across age groups
23473832	2013	Review	Eur J Paediatr Neurol	Current pharmacological treatment options for Tourette syndrome with comorbid ADHD
37378108	2023	Case Series	Cureus	Combination of guanfacine and aripiprazole associated with significant tic improvement in 3 TS patients
30899317	2019	Case Report	Ann Gen Psychiatry	Guanfacine monotherapy effective for ADHD/ASD comorbid with Tourette syndrome
16229000	2006	Case Series (Safety)	Mov Disord	4 children with Tourette syndrome experienced syncope while on guanfacine, likely drug-induced hypotension/bradycardia

US Market Information

Guanfacine is currently not licensed or marketed in Taiwan — no authorization records exist in this evidence pack (0 NDAs on file).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Guanfacine has direct, guanfacine-specific clinical trial evidence in Tourette syndrome (a completed Phase 3 RCT and a completed Phase 4 pilot), reinforced by a placebo-controlled pilot RCT and multiple systematic reviews/clinical guidelines that already recommend alpha-2 agonists as a tic-suppression option. The evidence base is mature rather than purely model-generated, but a documented safety signal (guanfacine-associated syncope, PMID 16229000) and the absence of Taiwan regulatory/safety data warrant guardrails before proceeding.

To proceed, the following is needed:

TFDA-equivalent package insert warnings and contraindications (currently a Blocking data gap)
Formal DrugBank/MOA documentation
Drug-drug interaction (DDI) data (current query returned no results)
Taiwan licensing/regulatory pathway assessment, since guanfacine is not currently marketed in Taiwan
Cardiovascular monitoring plan given the documented hypotension/bradycardia/syncope risk
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.